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Anti-angiogenic agents are biological drugs used for treatment of retinal neovascular
degenerative diseases. In this study, we aimed at in silico analysis of interaction of
vascular endothelial growth factor A (VEGFA), the main mediator of angiogenesis,
with binding domains of anti-angiogenic agents used for treatment of retinal diseases,
such as ranibizumab, bevacizumab and aflibercept. The analysis of anti-VEGF/VEGFA
complexes was carried out by means of protein-protein docking and molecular
dynamics (MD) coupled to molecular mechanics-Poisson Boltzmann Surface Area
(MM-PBSA) calculation. Molecular dynamics simulation was further analyzed by protein
contact networks. Rough energetic evaluation with protein-protein docking scores
revealed that aflibercept/VEGFA complex was characterized by electrostatic stabilization,
whereas ranibizumab and bevacizumab complexes were stabilized by Van der Waals
(VdW) energy term; these results were confirmed by MM-PBSA. Comparison of
MM-PBSA predicted energy terms with experimental binding parameters reported in
literature indicated that the high association rate (Kon) of aflibercept to VEGFA was
consistent with high stabilizing electrostatic energy. On the other hand, the relatively
low experimental dissociation rate (Koff) of ranibizumab may be attributed to lower
conformational fluctuations of the ranibizumab/VEGFA complex, higher number of
contacts and hydrogen bonds in comparison to bevacizumab and aflibercept. Thus,
the anti-angiogenic agents have been found to be considerably different both in terms
of molecular interactions and stabilizing energy. Characterization of such features can
improve the design of novel biological drugs potentially useful in clinical practice.
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INTRODUCTION
Vascular endothelial growth factor (VEGF) plays a pivotal role in angiogenesis through activation
of specific receptors (VEGFR). Among different VEGF isoforms, VEGFA (VEGF165) is the isoform
that has principally been involved in angiogenesis. Angiogenesis is the physiological process of
formation of new vessels from pre-existing ones and is crucial during development or tissue repair,
but detrimental in some disease states. Therefore, in some pathological conditions angiogenesis
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inhibition is a relevant therapeutic goal (Carmeliet and Jain,
2011). Anti-VEGF agents are used to inhibit primary tumor
and metastasis growth (Chung and Ferrara, 2011), both in
adjuvant, and more recently, in neoadjuvant settings (Welti
et al., 2013). Recently, anti-angiogenic agents have been used to
treat ocular pathological conditions such as age-related macular
degeneration (AMD) and diabetic macular edema (DME) (Holz
et al., 2014; Stewart, 2014a). Diabetic retinopathy is a leading
cause of vision loss of working-age adults, and DME is the
most frequent cause of vision loss related to diabetes. AMD
is a progressive multifactorial neurodegenerative disease that
impairs the visual field. Currently, three VEGF inhibitors
are used to treat retinal disorders characterized by neovessel
formation: ranibizumab (Lucentis R©), aflibercept (Eylea R©) and
bevacizumab (Avastin R©), this latter is used off-label (Figure 1).
Furthermore, several new anti-angiogenic agents are in clinical
development (Teicher, 2011; Hanout et al., 2013; Li et al.,
2014). Bevacizumab is a humanized monoclonal antibody,
ranibizumab is the mutated Fab (Fragment antigen-binding)
of the monoclonal antibody (Ab) originating bevacizumab and
aflibercept is a fusion protein that works as decoy VEGF receptor
(Figure 1). Ranibizumab has been developed for intravitreal
injection and shows improved ocular pharmacokinetics (Xu
et al., 2013) compared to bevacizumab. X-ray structures of
VEGFA bound to ranibizumab (PDB: 1CZ8) (Chen et al., 1999)
or Fab-bevacizumab (PDB: 1BJ1) (Muller et al., 1998) have
been solved. The three dimensional structure of aflibercept
is not available, albeit widely investigated. Aflibercept, also
known as VEGF-trap, is a decoy receptor where two binding
domains, the domain 2 (d2) of VEGFR1 and the domain 3
(d3) of VEGFR2 (from N-terminus to C-terminus of primary
sequence) are connected to the fragment crystallizable region
(Fc) of human immunoglobulin (Ig) (Holash et al., 2002).
Throughout the text the binding domain of aflibercept is named
“VEGFR1d2_R2d3.”
Iyer et al. (2010) reported the x-ray structure of VEGFR1
domain 2, as binary complex with VEGFB, while Leppänen
et al. (2010) have solved the x-ray structure of VEGFR2
domain 2 and 3 (VEGFR2d2_d3) in complex with VEGFC,
that we used for homology modeling of aflibercept’s binding
domain (VEGFR1d2_R2d3). However, in silico comparison of
anti-VEGF/VEGFA complexes has not yet been carried out.
Therefore, the aim of our study was to test the hypothesis
that the three anti-VEGF/VEGFA complexes, involving
ranibizumab, bevacizumab or aflibercept have different
energy terms corresponding to different molecular and/or
atomic interactions. To this end we carried out protein-
protein docking with the software PyDock (Cheng et al.,
2007; Jiménez-García et al., 2013), simulation of complexes
Abbreviations: VEGF(A,B,C. . . ), Vascular endothelial growth factor and its
isoforms; VEGFR (1, 2. . . ), VEGF receptor and its isoforms; anti-VEGF,
Drugs that block VEGF; AMD, Age related macular degeneration; DME,
Diabetic macular edema; VEGFR1d2_D2d3, Aflibercept’s binding domain; Fab-
bevacizumab, Bevacizumab’s binding domain; Fab, Fragment antigen-binding;
Fc, Fragment crystallizable region; Ig, Human immune globulin; MD, Molecular
dynamics; g_mmpbsa, Tool for molecular mechanics Poisson Boltzmann Surface
Area calculations (MM-PBSA).
with molecular dynamics (MD, GROMACS, Pronk et al.,
2013) and molecular mechanics Poisson-Boltzmann surface
area calculation (MM-PBSA) by using the g_mmpbsa tool
(Kumari et al., 2014). Furthermore, we have added the analysis
of the protein contact networks (Vishveshwara et al., 2009;
Di Paola et al., 2013) on MD trajectories, to analyze the
correlation of key topological properties over the time. Our
results show that the three anti-angiogenic agents considerably
differ, both in terms of molecular interactions and stabilizing
energy; furthermore our in silico data are consistent with
published experimental binding parameters (Papadopoulos et al.,
2012).
METHODS
Molecular Modeling and Protein-protein
Docking
Full protein sequences of Fab-bevacizumab binding domain
and ranibizumab were retrieved from the DrugBank database
(http://www.drugbank.ca, accession numbers: DB00112 and
DB01270, respectively). The sequence of aflibercept binding
domain (VEGFR1d2_R2d3) was built by connecting the
sequences of domain 2 of human VEGFR1 and domain 3 of
human VEGFR2:
SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLK
KFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNG
HLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTART
ELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLST
LTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEDPIEGR.
Structures of Fab-bevacizumab and ranibizumab binding
domains were modeled by means of the SwissModel web server
(http://swissmodel.expasy.org/; Schwede et al., 2003) using,
respectively, the x-ray structures of bevacizumab (PDB: 1BJ1) and
ranibizumab (PDB: 1CZ8) in complex with the dimer of VEGFA
as templates. This procedure included the modeling of short
loops, which are lacking in the X-ray structures. The structure
of VEGFR1d2_R2d3 was modeled using the x-ray structure
of VEGFR2 in complex with VEGFC (PDB: 2X1W). Protein-
Protein docking was carried out through the pyDockWEB
(http://life.bsc.es/servlet/pydock/home/; Jiménez-García et al.,
2013). The 3D coordinates of the ligand, the VEGFA dimer,
were extracted from the crystal structure of VEGFA bound to
ranibizumab (1CZ8). Homologymodels of Fab-bevacizumab and
ranibizumab were set as PDB files of receptors. The complex
VEGFR1d2_R2d3/VEGFA was built by using two randomly
selected frames, belonging to relative conformational minimum
of a preliminary MD of VEGFR1d2_R2d3 (Supplementary
Material). Because of the low RMSD (0.06 nm), no differences
were found between the two predicted complexes of the two
analyzed frames. In order to evaluate the effectiveness of MD on
VEGFR1d2_R2d3 structural optimization, the protein-protein
docking of VEGFR1d2_R2d3 was also carried out using its
starting model.
Given the 3D coordinates of two interacting proteins,
pyDockWEB uses FTDock for generation of the predicted
complexes by rigid-body docking (Gabb et al., 1997). No restrains
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FIGURE 1 | Schematic structures of ranibizumab (A), bevacizumab (B), and aflibercept (C). Ab stands for antibody, Fab stands for fragment antigen binding,
Fc stands for fragment crystallizable region. R1d2 stands for domain 2 of vascular endothelial growth factor receptor VEGFR1 and R2d3 stands for domain 3 of
VEGFR2. Black bars correspond to inter-chain disulfide bridges.
have been applied in this stage. The predicted complexes were
then evaluated by PyDock scoring function, which includes
electrostatics, desolvation energy and limited Van der Waals
(VdW) contributions (Cheng et al., 2007).
Molecular Dynamics Simulation (MD)
All-atom MD has been carried out with GROMACS 4.6 (Pronk
et al., 2013), taking advantage of graphic processing unit (GPU)
acceleration. Disulfide bridges in the object molecules were
built as follows: VEGFA (Cys26-68Cys, Cys102-52Cys, Cys102-
57Cys) in each monomer; Fab-bevacizumab and ranibizumab
(Cys23-88Cys and Cys134-194Cys in L chain, Cys22-96Cys
and Cys150-206Cys in H chain); VEGFR1d2_R2d3 (Cys30-
79Cys in R1d2 and Cys189-125Cys in R2d3). Ionization state
of residues was assigned at pH 7.4, OPLS-AA (Jorgensen et al.,
1996) force field parameters were assigned to protein; thereafter,
the following simulation protocol was applied: (i) building of
the simulation system (explicit solvation with water molecules,
SPC-E model (Berendsen et al., 1987), and neutralization with
NaCl 150mM); (ii) 2000 steps of steepest descent energy
minimization (time-step= 1 fs); (iii) 500 ps of NVT equilibration
(time-step= 1 fs); (iv) 500 ps of NPT equilibration (time-
step= 1 fs); v. production runs (time-step= 2 fs). In order
to use a 2 fs time-step we applied LINCS constraints (Hess
et al., 1997) through the P-LINCS algorithm (Hess, 2008).
Long-term electrostatic interactions were treated by applying
the Particle Mesh Ewald (PME) method (Cheatham et al.,
1995) (pme_order = 4; fourier spacing 0.16). Temperature
was kept constant at 300K with Berendsen thermostat applied
to two groups (protein and non-protein), pressure was
controlled by the Parinello-Rahman barostat (P = 1 bar; water
compressibility 4.5 E-5 bar−1). Trajectory and energy outputs
were collected every 10 ps. Three independent replicas for each
MD were carried out: VEGFR1d2_R2d3 (40 ns), ranibizumab
(20 ns), Fab-bevacizumab (20 ns), VEGFR1d2_R2d3/VEGFA
complex (20 ns), ranibizumab/VEGFA complex (20 ns), Fab-
bevacizumab/VEGFA complex (40 ns). VEGFA was simulated
for just 3 ns, because the RMSD, secondary structure and
cosine content indicated an equilibrated simulation. MD runs
were launched on the EURORA machine (HPC-CINECA)
using an average of 64 CPUs, 8 GPUs and 8 message passing
interface (MPI) processes per run. Visual analysis of trajectories
was carried out with Visual Molecular Dynamics VMD 1.9
(Humphrey et al., 1996); whereas analysis of MD simulations was
carried out with the analysis package of GROMACS 4.6 (Pronk
et al., 2013). We carried out Principal Component Analysis
(PCA) of trajectories for characterization of principal collective
motions of the analyzed molecules; such motions can identify
the movement of a domain toward another domain of a given
protein (Amadei et al., 1993). Each principal component is
also named eigenvector to which an eigenvalue (∼frequency) is
associated. Eigenvectors were projected in the MD trajectories
in order to visualize the collective motions of the protein,
thereby reducing the dimensionality of trajectories. Because PCs
with high cosine content are indicative of random diffusive
movement (Hess, 2002; Neugebauer et al., 2002), in order to
assess the correct conformational sampling of trajectories, cosine
content of the first two PCs has been determined. A cosine
content lower than 0.5 is considered as indicative of satisfactory
conformational sampling. The number of contacts at protein-
protein interface have been determined with g_mindist tool of
GROMACS, residues were defined as interacting at 3.5 Å. High
frequency H-bonds at the protein-protein interface have been
analyzed using the HBonanza open source software (Feenstra
et al., 1999). RMSD (Figures 2, 4) calculations have been
carried out by selecting Cα carbons of proteins and excluding
the analysis of translational and rotational movements. The
splitting of RMSD (Figure 4), of VEGFA/anti-VEGF trajectories,
was obtained as follows: we launched the command g_rms
using the gromacs index.ndx file in order to carry out the
calculation on each component of complexes, the VEGFA
and the anti-VEGFA, respectively; therefore RMSD profiles of
complexes in Figure 2 are not the sum of split RMSD in
Figure 4.
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FIGURE 2 | Root-mean-square deviation (RMSD) profile of simulated molecules. (A) ranibizumab; (B) Fab-Bevacizumab; (C) VEGFR1d2_R2d3; (D)
ranibizumab/VEGFA complex; (E) Fab-bevacizumab/VEGFA complex; (F) VEGFR1d2_R2d3/VEGFA complex; (G) VEGFA replica 1; (H) VEGFA replica 2; (I) VEGFA
replica 3. Black line corresponds to the first replica, red line corresponds to the second replica, green line corresponds to the third replica.
Protein Contact Networks
The analysis was applied to 100 frames, 10 ps-spaced, taken
from the last 10 ns of each MD replica; whereas MD of
VEGFA was analyzed in the whole 3ns-replicas. Each frame
was converted into an indirect, unweighted graph, whose nodes
are the α-carbons and edges represent the mutual spatial
distances between residues when their distance is within 4 and
8 Å, accounting to VdW interactions. This method, applied
in a previous work to highlight the allosteric character of
protein-ligand complexes (De Ruvo et al., 2012), accounts
only for non-covalent bonds. After the definition of the
protein contact network, the following global (whole structure)
topological descriptors and a chemical-physical descriptor were
derived:
(1) adeg (average degree): the average number of contacts
involving a single residue;
(2) asp (average shortest path): the shortest path between two
residues indicates the minimum number of steps (links)
from one residue to another; asp is the average value over
all residue pairs;
(3) E (the Graph Energy): couples the graph global connectivity
to the interactions in the represented molecular structure
(Balakrishnan, 2004);
(4) dGsolv (free solvation energy): quantitative descriptor of
protein stability in water (Eisenberg and McLachlan, 1986),
takes into account the overall energy gain of atoms passing
from protein to water.
In order to assess whether MD reached a relative conformational
minimum, the correlation pattern of topological descriptors and
energy (dGsolv) was analyzed over the time; the conformational
minimum is characterized by a non-significant correlation
coefficient of the variables. Furthermore, the protein contact
network has been partitioned into clusters, according to a spectral
clustering algorithm, which was previously applied to split the
protein structure into functional modules. This method is able to
detect functional domains in protein structures and complexes,
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along to the topological role of single residues that account for
inter- and intra-module interaction (Tasdighian et al., 2014).
Clustering results for each average structure of complexes and
protein systems is represented as a partition color map of a two-
dimensional matrix of cluster distribution along the sequence.
Background (blue) corresponds to residues that do not belong
to the same cluster. Residues belonging to the same cluster
are represented with the same color. An interruption between
cluster-sequence continuity, i.e., a residue shifting to a different
cluster, which corresponds to a long-range contact, is represented
as a projection termed “whisker.”
MM-PBSA and Energy Decomposition
The MM-PBSA method calculates the three energetic terms of
the binding free energy (Equation 1) (Kollman et al., 2000):
1Gbinding = Gcomplex − (Gprotein + Gligand) (1)
Free energy of either products or reagents is calculated taking in
account three terms (Equation 2):
Gx =< E MM > + < Gsolvation > −TS (2)
Where EMM is the vacuum potential energy and Gsolvation is the
free energy of solvation. EMM includes Ebonded and Enon−bonded
energies; Enon−bonded energy is the summation of Van der Waals
(Lennard-Jones potential function) and electrostatic (Coulomb
potential function) energy terms. Gsolvation, is characterized
by the summation of two terms, Gpolar and Gapolar, which
represent the electrostatic and the non-electrostatic term. Gpolaris
calculated using a continuum implicit solvent model applying the
Poisson-Boltzmann equation (Baker et al., 2001). TheGapolarterm
results from the summation of Gcavity and GVdW terms; Gcavity
is the work done by the solute to create a cavity in the solvent,
GVdW is the attractive Van derWaals energy between solvent and
solute. Gapolar accounts for the hydrophobic effect (Richmond,
1984). Single trajectory MM-PBSA calculations were carried out
on each of the three MD replicas of complexes by using the
g_mmpbsa tool (Kumari et al., 2014), which integrates functions
from GROMACS and APBS (http://rashmikumari.github.io/g_
mmpbsa/). The dielectric relative constant ε has been set to 3
for protein and 80 for water (Kukic et al., 2013). The solvent
accessible surface area (SASA)method was used for calculation of
Gapolar; the surface tension constant γ was set to 0.022KJ/mol Å2
(Nicholls et al., 1991). The current implementation of the MM-
PBSA method in g_mmpbsa does not include calculation of the
entropic term (S) in the equation 2; indeed, g_mmpbsa is unable
to provide prediction of absolute binding free energy, providing
mainly relative binding energies. For this reason, we use through
the text the notation “1Ebinding” instead of “1Gbinding,” this
latter would include entropy. The g_mmpbsa tool predicts the
contribution of residues to the binding free energy by means
of energy decomposition calculations; it allows the visualization
of such results by means of common molecular visualization
tools. The energy contribution is written in the b-factor field
of the.pdb file and can be mapped in a 3D structure. MM-
PBSA was applied to 100 frames, 10 ps-spaced, taken from the
last 10 ns of each MD replica. The hardware used for these
calculations was a Desktop PC (12 core Intel i7, 64 GB RAM,
two GeForce GTX 680-SLI) launching 16 MPI processes per
job with maximum available performance (8 h per calculation,
2% load memory).
Statistical and Graphical Analysis
GraphPad (version 6; San Diego, CA, USA) was used to carry
out statistical analysis and graph creation. Comparisons between
two independent groups were made by unpaired Student’s t-
test; p < 0.05 were considered significant. RMSD graphs have
been created with xmgrace (open GNU license). Figures have
been created with OPEN PyMOL Molecular Graphics System,
Schrödinger, LLC (New York, NY, USA).
RESULTS
Homology Modeling and Protein-protein
Docking
Modeled structures of Fab-bevacizumab and ranibizumab
showed low root mean square deviation (RMSD), respectively
0.003 nm and 0.002 nm, upon superimposition on PDB:
1BJ1 and PDB: 1CZ8 x-ray structures, respectively. The
model of VEGFR1d2_R2d3 showed low RMSD (0.04 nm)
upon superimposition on the corresponding template
PDB:2X1W. VEGFR1d2_R2d3 was subjected to short all-
atomMD simulation prior protein-protein docking with VEGFA
(Supplementary Material, Figure S1). Protein-protein docking
predictions were carried out with PyDock. The software was
first validated by building complexes of Fab-bevacizumab
and ranibizumab with VEGFA. RMSDs between the best
scored Fab-bevacizumab/VEGFA and ranibizumab/VEGFA
complexes and the correspondent x-ray structures were
negligible (0.046 and 0.045 nm respectively). Subsequently
we modeled the VEGFR1d2_R2d3/VEGFA complex. When
compared to the starting model, MD simulation gave a better
docking score for VEGFR1d2_R2d3 (Table 1). The complex
VEGFR1d2_R2d3/VEGFA was compared to X-ray structures
of VEGFR2 bound to VEGFC and VEGFA (PDB: 2X1W and
PDB: 3V2A, respectively; Supplementary Material, Figure
S2). Rough energetic evaluation of predicted complexes,
obtained with PyDock, is shown in Table 1. Notice that
VEGFR1d2_R2d3/VEGFA was stabilized by electrostatic
interaction energy compared to Fab-bevacizumab/VEGFA
and ranibizumab/VEGFA complexes, which were rather
characterized by stabilizing desolvation and VdW energy terms.
Molecular Dynamics Simulation (MD)
Three independent MD replicas of VEGFA, ranibizumab, Fab-
bevacizumab, VEGFR1d2_R2d3 and of the corresponding 1:1
complexes with VEGFA were carried out. Ranibizumab and
Fab-bavacizumab reached a relative minimum within 10 ns
(Figures 2A,B), VEGFR1d2_R2d3 reached a relative minimum
within 40 ns (Figure 2C). The great conformational fluctuation
of unbound VEGFR1d2_R2d3 is mainly related to rotational
freedom of the connecting hinge between domains R1d2 and
Frontiers in Pharmacology | www.frontiersin.org 5 October 2015 | Volume 6 | Article 248
Platania et al. VEGF-A and anti-angiogenic drugs interaction
TABLE 1 | Energetic contribution to PyDock score.
Complex Electrostatic Desolvation VdW RMSD
energy energy (kcal/ (nm)
(kcal/mol) (kcal/mol) mol)
Ranibizumab/VEGFA −7 −24 −76 0.05 vs. 1CZ8
Fab-bevacizumab/VEGFA −8 −20 −62 0.05 vs. 1BJ1
*VEGFR1d2_R2d3/VEGFA −22 −9 19 0.30 vs. 2X1W
0.20 vs. 3V2A
**VEGFR1d2_R2d3/VEGFA −11 −12 34 0.40 vs. 2X1W
0.50 vs. 3V2A
VdW (Van der Waals interaction energy), RMSD (root-mean-square deviation).
*Aflibercept binding domain optimized with MD.
**Aflibercept binding domain without structural optimization.
TABLE 2 | Cosine content of the first two PCs of molecular dynamics
simulations.
Replica I Replica II Replica III
PC1 PC2 PC1 PC2 PC1 PC2
VEGFA 0.35 0.01 0.22 0.05 0.36 0.02
Ranibizumab 0.36 0.15 0.02 0.25 0.04 0.32
Fab-bevacizumab 0.35 0.24 0.50 0.20 0.36 0.02
VEGFR1d2_R2d3 0.18 0.14 0.01 0.02 0.46 0.01
Ranibizumab/VEGFA 0.01 0.32 0.13 0.30 0.35 0.15
Fab-bevacizumab/VEGFA 0.34 0.03 0.42 0.16 0.37 0.13
VEGFR1d2_R2d3/VEGFA 0.10 0.36 0.36 0.38 0.24 0.32
PC stands for Principal Component.
R2d3, and to inter-conversion of turns to coil and vice-
versa, of the loops in R1d2 domain (see also Supplementary
Material, Figures S3–S5). Fab-bevacizumab/VEGFA complex was
characterized in all three replicas by an RMSD higher than
the other complexes (Figure 2E), despite each replica reached a
relative minimum after about 10 ns simulation, as did the other
complexes (Figure 2); VEGFA reached a relative conformational
equilibrium in 3 ns (Figures 2G–I).
The secondary structures of unbound VEGR1d2_R2d3 and
Fab-bevacizumab/VEGFA did not significantly change over the
time (Supplementary Material, Figures S3–S8).
In order to characterize the principal collective motions of
proteins and their respective macromolecular complexes we
carried out PCA of covariance matrix of trajectories. The first six
eigenvectors explained about 99% of variance of each simulation.
The first principal component (PC1) was projected into the MD
trajectory of each simulated molecule (videos in Supplementary
Material). In order to verify the correct conformational sampling
of MD cosine content of the first two eigenvectors of each
trajectory was analyzed (Table 2). Because cosine content of PC1
and PC2 was lower than 0.4 (cut-off 0.5), we assumed that
conformational sampling of all MD runs was satisfactory.
Protein Contact Networks Analysis
To confirm that the systems were analyzed at relative
conformational minimum, topological descriptors of protein
contact network were also analyzed. The results of correlation
analysis between topological descriptors and time for complexes
are reported in Table 3 (for unbound systems see also
Supplementary Material, Table S1). The energetic descriptor
dGsolv did not change over the time, such that the correlation
dGsolv vs. time was not significant.
In contrast, some topological descriptors showed correlations
with time and/or each other. Indeed, the average shortest path asp
positively correlated with time (0.61), while the average degree
adeg and the graph energy E showed, respectively, a positive and
a negative correlation in ranibizumab complex. The topological
descriptors adeg and asp showed negative correlations (-0.60
and -0.54, respectively) with time in VEGFR1d2_R2d3. Finally,
strong correlation between E and adeg for all complexes indicated
that the graph energy E describes the overall connectivity energy.
After partitioning of the protein contact network into clusters
the structure of the complexes was represented as functional
modules. Figure 3 reports the clustering of VEGFA (partitioned
in two clusters) and all complexes (partitioned in four clusters).
Clustering of unbound anti-VEGFs is reported in Supplemental
Material (Figure S9).
The VEGFA partition in two clusters revealed that they were
intermingled (Figure 3A). VEGFR1d2_R2d3/VEGFA partition
in four clusters (Figure 3B) revealed a conserved network
for VEGFA and two distinct domains corresponding to
R1d2 and R2d3, with a lot of long-range interactions with
VEGFA (Figure 3B). The partition in four clusters of Fab-
bevacizumab/VEGFA (Figure 3C) and ranibizumab/VEGFA
(Figure 3D), revealed for bound VEGFA a partition that differ
from that of unbound VEGFA, while some whiskers projected
from VEGFA to Fab-bevacizumab and ranibizumab modules;
furthermore, a greater number of long-range interactions was
formed between ranibizumab and VEGFA in comparison to
Fab-bevacizumab.
MM-PBSA Calculation
An in-depth analysis of MD data was carried out withMM-PBSA
calculations. GROMACS output files were directly analyzed with
the g_mmpbsa tool. The estimated binding energy1Ebinding and
its contributing terms were compared to experimental binding
and kinetic parameters (Table 4; Papadopoulos et al., 2012).
The relationship between KD and binding energy is given
by: 1G = RT ln KD at 1M concentration, where R is the
ideal gas constant and T is the absolute temperature. In Table 4
1Ebinding is reported instead of 1Gbinding, because the entropic
term is not included. The comparison of experimental KD
with predicted 1Ebinding confirmed a most favorable binding
energy for VEGFR1d2_R2d3 compared to ranibizumab and Fab-
bevacizumab bound to VEGFA. The differences in 1Ebinding
for ranibizumab/VEGFA and Fab-bevacizumab/VEGFA vs.
VEGFR1d2_R2d3/VEGFA were significant (t-test respectively
p = 0.003 and p = 0.004). Because 1Ebinding results
as summation of different energy terms, we analyzed each
single energy term; interestingly, there was a correlation
between experimental KD and 1GApolar (apolar contribution
to desolvation energy), suggesting that the hydrophobic effect
substantially accounts for affinity. As reported in Table 1, a
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TABLE 3 | Correlation analysis of topological parameters of anti-vegf/VEGFA complexes.
Ranibizumab/VEGFA Fab-bevacizumab/VEGFA VEGFR1d2_R2d3/VEGFA
t adeg asp E dGsolv t adeg asp E dGsolv t adeg asp E dGsolv
t – 0.20 0.61 0.07 −0.12 – −0.12 0.29 −0.20 −0.30 – −0.60 0.35 −0.54 0.46
adeg – – −0.18 0.94 −0.47 – – −0.13 0.91 −0.33 – – −0.63 0.93 −0.51
asp – – – −0.28 0.07 – – – −0.17 0.05 – – – −0.61 0.34
E – – – – −0.50 – – – – −0.28 – – – – −0.45
dGsolv – – – – – – – – – – – – – – –
FIGURE 3 | Clustering of protein contact networks. Distribution of clusters along sequence in a matricial space. Partition color maps of (A). VEGFA (200 nodes),
(B). VEGFR1d2_R2d3/VEGFA, (C). Fab-bevacizumab/VEGFA, (D). ranibizumab/VEGFA. The first 200 nodes in complexes corresponds to bound VEGFA. In (A) green
and light blue clusters corresponds to VEGFA. In (B–D) dark red and orange are clusters of anti-VEGF. Residues (nodes) belonging to the same cluster have the same
color, long projections “whiskers” in the map represent residues shifting to a different cluster with respect to that of neighbors in sequence. The background is dark
blue and characterizes residues that are not in the same cluster.
relevant electrostatic stabilization was predicted by PyDock for
the VEGFR1d2_R2d3/VEGFA complex, a data confirmed by
MM-PBSA (Table 4). Furthermore, the higher Kon of aflibercept
(410 M−1 s−1), as compared to ranibizumab (1.6 M−1 s−1)
and bevacizumab (5.6 M−1 s−1), was consistent with the
favorable electrostatic component of the binding energy, because
the association rate of proteins is known to be related to
electrostatic forces (Wade et al., 1998; Zhou, 2001; Pan et al.,
2013). Polar contribution to the solvation energy (and to
the whole 1Ebinding) is positive, i.e., unfavorable, because of
the polar/charged residue transition to a more hydrophobic
environment; however, despite the 1Gpolar is more positive
for VEGFR1d2_R2d3/VEGFA than for ranibizumab/VEGFA
and Fab-bevacizumab/VEGFA, 1Eelectrostatic-1Gpolar gives a
favorable gain only forVEGFR1d2_R2d3/VEGFA. Compensation
of favorable electrostatic and unfavorable polar desolvation
energy terms is commonly found in complex formation,
while most stabilization arises from non-polar interactions and
hydrophobic effect (Ozboyaci et al., 2011; Spiliotopoulos et al.,
2012; Kar et al., 2013). Another information provided by the
PyDock prediction was the substantial favorable VdW energy
term for ranibizumab/VEGFA and Fab-bevacizumab/VEGFA
(Table 1); this observation was confirmed by MM-PBSA
(Table 4). Furthermore, VdW energy did not appear to be
correlated to any kinetic binding parameter.
Dissociation Rate of Complexes
A lower dissociation rate is reported for ranibizumab/VEGFA
compared to the other two complexes (Papadopoulos et al.,
2012). The number of contacts at protein-protein interface
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TABLE 4 | MM-PBSA results compared to experimental binding parameters.
Complex Binding parameters MM-PBSA energy terms (KJ/mol)
Kon/105 (M−1 s−1) Koff/10
−5 (s−1) KD (pM) 1Ebinding 1EVdW 1Eelectrostatic 1GPolar 1GApolar
Ranibizumab/VEGFA 1.60 0.73 46 −7.0± 40 −4.8± 5 −1.0± 20 410 ± 30 −5.2± 7
Fab-bevacizumab/VEGFA 5.30 3.10 58 −8.7± 30 −3.2± 10 −2.2± 20 343 ± 30 −5.6± 7
VEGFR1d2_R2d3/VEGFA 410 2.01 0.49 −14.0± 90 −3.7± 50 −14.3± 1.0 1050 ± 100 −7.0± 40
Kinetic and binding parameters are from Papadopoulos et al. (2012).
TABLE 5 | High frequency H-bonds at anti-VEGF/VEGFA interfaces.
Anti-VEGF/VEGFA
Ranibizumab Tyr102/Glu93; Tyr101/Glu93; Tyr101/Glu79; Ser106/His90;
Tyr99/Glu87; Tyr96/Glu87; Tyr34/Glu89; Thr53/Glu89;
Tyr54/Tyr21; Trp50/His89.
Fab-bevacizumab His101/Glu93; Tyr102/Glu93; Ser106/His90; Thr53/Gln89;
Tyr54/Tyr21.
VEGFR1d2_R2d3 Arg96/Asp93; Gln97/Lys107; Glu73/Arg105; Glu73/Arg103.
In the couple X/Y, X, and Y are respectively the residues of anti-angiogenic agent and
VEGFA, involved in the H-bond.
of complexes at 3.5 Å were determined by the g_mindist tool
of GROMACS, while the number of H-bond was assessed
by Hbonanza. The number of contacts resulted as follows:
Ranibizumab/VEGFA, 480.7 ± 0.5; Fab-bevacizumab/VEGFA,
436.5 ± 0.4; VEGFR1d2_R2d3/VEGFA, 289.9 ± 1.8. The
number of H-bonds, whose location is reported in Table 5,
were: Ranibizumab/VEGFA, 10; Fab-bevacizumab/VEGFA, 5;
VEGFR1d2_R2d3/VEGFA, 4. This analysis suggested that the
complex Ranibizumab/VEGFA might be more stable than the
other two complexes, in terms of residency time. To test this
hypothesis we further analyzed the profiles of complexes by
splitting the RMSD for each interacting protein. As shown in
Figure 4, ranibizumab in the complex ranibizumab/VEGFA
had the lowest RMSD, Fab-bevacizumab in the complex
Fab-bevacizumab/VEGFA had an intermediate RMSD,
VEGFR1d2_R2d3 in the complex VEGFR1d2_R2d3/VEGFA
had the highest RMSD. Further analysis was carried out by
calculating the residue-based root mean square fluctuation
(RMSF) over the whole simulations. The residue-based RMSF of
complexes was visualized into 3D structures (Figure 5).
The visualization of RMSF confirmed less structural
fluctuation of ranibizumab/VEGFA compared to Fab-
bevacizumab/VEGFA, consistent with their difference in
experimental Koff, and RMSD profiles. The representation of
residue-based RMSF of VEGFR1d2_R2d3/VEGFA showed
that VEGFA is mainly stabilized at the contact surface
with domain 2 and domain 3 (Figure 5A); a high degree of
fluctuation, however, detectable out of the contact region, may
account for the conformational flexibility of VEGFR1d2_R2d3.
Ranibizumab/VEGFA showed less conformational flexibility
compared to both VEGFR1d2_R2d3/VEGFA and Fab-
bevacizumab/VEGFA, suggesting a higher conformational
stability of the complex (Zheng et al., 2006). The lower Koff of
ranibizumab/VEGFA is in accordance with the dependency of
the residence time τ (1/Koff) on the conformational stabilization
of the complex (Copeland, 2011).
Energy Decomposition
Anti-VEGF/VEGFA complexes were further analyzed by looking
at residues that favorably contribute to 1Ebinding, by means
of energy decomposition calculation. Results were visualized
in terms of b-factor (Figure 6). “Hot-spots,” i.e., residues that
contribute significantly to complex stabilization (Clackson and
Wells, 1995), were identified. As expected, the area that shows
the highest stabilization was identified in the contact surface
between anti-VEGF and VEGFA. Table 6 shows residues of
anti-VEGFs that contribute to stabilization of complexes. The
mutations (Ser105Thr; His101Tyr, Asn31His) carried out on
Fab-bevacizumab to obtain ranibizumab (Yu et al., 2011),
resulted in about a two-fold higher energy stabilization for
the ranibizumab/VEGFA complex (Table 6). Interestingly, the
stabilizing residues of VEGFR1d2_R2d3 bound to VEGFA are all
basic amino acids, confirming the substantial contribute of the
electrostatic contribution to the overall 1Ebinding, as mentioned
above.
DISCUSSION
The main object of this study was the computational analysis,
at molecular level, of binding between VEGFA and the three
available anti-VEGF drugs, namely ranibizumab, bevacizumab
(Fab-bevacizumab) and aflibercept (VEGFR1d2_R2d3). We have
limited our study to interaction between VEGFA and binding
domains of the above mentioned anti-VEGF drugs, excluding
the Fc fragment of aflibercept and bevacizumab, because the
Fc fragment does not seem to influence the pharmacodynamic
properties of these drugs (Stewart, 2014b). Wu et al. (2013)
already reported themodeling of cobercept (Li et al., 2014), which
binds VEGFA with domains VEGFR1d2_R2d3_R2d4, however,
no studies have analyzed in detail the energy components
contributing to the complex VEGFR1d2_R2d3/VEGFA or
compared complexes of different anti-VEGF agents. Therefore,
the present study, for the first time, compares the interaction
of the three different anti-VEGF agents with VEGFA; this is
particularly relevant, considering that aflibercept is structurally
unrelated to the other two agents. The entire computational study
was carried out with open source tools and software packages.
Protein-protein docking, carried out with PyDock, was
the first step. The rough energetic evaluation of complexes
Frontiers in Pharmacology | www.frontiersin.org 8 October 2015 | Volume 6 | Article 248
Platania et al. VEGF-A and anti-angiogenic drugs interaction
FIGURE 4 | Representative graphs of split RMSD of VEGFA (black line) and anti-VEGF (red line) binding domains. (A) Split RMSD for the ranibizumab/
VEGFA complex; (B) split RMSD for Fab-bevacizumab/VEGFA complex; (C) split RMSD for VEGFR1d2_R2d3/VEGFA complex.
FIGURE 5 | Residue based-root mean square fluctuations (RMSF) of complexes. RMSF increases from blue to red color. Bound VEGFA molecule is
highlighted with a red circle. (A) VEGFR1d2_R2d3/VEGFA. (B,C) Fab-bevacizumab/VEGFA, respectively from top and side view. (D,E) Ranibizumab/VEGFA
respectively, from top and side view.
predicted by PyDock showed substantial difference between
VEGFR1d2_R2d3, ranibizumab and Fab-bevacizumab,
VEGFR1d2_R2d3/VEGFA being stabilized mainly by
electrostatic energy, whereas the other two complexes were
stabilized by VdW and desolvation energy. MD simulation
(GROMACS) combined withMM-PBSA calculation (g_mmpbsa
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FIGURE 6 | Three-dimensional projection of energy decomposition results. (A) VEGFR1d2_R2d3/VEGFA. (B) Fab-bevacizumab/VEGFA. (C) Ranibizumab/
VEGFA. Stabilizing effect of residues decreases from blue (stabilizing negative energy) to red (destabilizing positive energy). Green or yellow identify neutral (close to
zero) contribution to the binding free energy. VEGFA bound to anti-VEGFA agents is highlighted by a black circle. Arrows highlight the areas of proteins with high RMSF.
tool) was the second step. All MD simulations have been
analyzed over a time sufficient to reach relative conformational
minimum. Some systems (unbound VEGFR1d2_R2d3 and
Fab-bevacizumab/VEGFA) showed high RMSD fluctuations,
though secondary structure was conserved and cosine content
of eigenvectors was low, indicating correct conformational
sampling. MM-PBSA calculations confirmed most of
results obtained with PyDock, such as the contribution of
electrostatic energy to stability of VEGFR1d2_R2d3/VEGFA
and the contribution of Van der Waals interaction energy
to ranibizumab/VEGFA and Fab-bevacizumab/VEGFA.
Furthermore, MM-PBSA provided energy contributions to
1Ebinding in good agreement with experimental binding data
(Papadopoulos et al., 2012). MM-PBSA calculation carried
out with g_mmpbsa seems at least as successful as other
existing tools for analysis of protein-protein docking and MD
(Spiliotopoulos et al., 2012; Corrada and Colombo, 2013), but
has the advantage of being implemented for GROMACS output
files. We obtained a good correlation between experimental
KD and apolar desolvation energy (1Gapolar), in accordance
to the leading role of solvent exclusion, which is strictly
related to the hydrophobic effect of inter- and intra-molecular
assembly (Richmond, 1984; Chandler, 2005). Breaking down
of 1Ebinding helped the identification of several features of
complexes. The kinetics of aflibercept/VEGFA binding has been
found to be characterized by fast Kon, which is consistent with
substantial favorable electrostatic forces (Papadopoulos et al.,
2012). Ranibizumab/VEGF-A had shown low experimental Koff
(Papadopoulos et al., 2012), i.e., long lasting binding, and this
could be related to higher number of contacts and H-bonds
and less conformational freedom compared to the other two
analyzed complexes (Copeland, 2011). The residue-based RMSF
confirmed that upon binding ranibizumab stabilizes VEGFA
in comparison to Fab-bevacizumab. VEGFR1d2_R2d3 also
stabilizes VEGFA; however, the C-terminal and the N-terminal
of VEGFR1d2_R2d3 are characterized by high RMSF, which
may account for the higher Koff of aflibercept. Furthermore, the
g_mmpbsa tool allowed us to identify the residues that favorably
contribute to binding energy. A similar approach was carried out
by Corrada and Colombo (2013) who have studied correlation
of energetic parameters with affinity maturation of 17 variants
of bevacizumab bound to VEGFA. A previous study reports two
single nucleotide polymorphisms (SNPs) that may influence the
binding at VEGFR2 (Wang et al., 2007):
• SNP1192G/A (rs2305948, in exon 7), that corresponds to a
mutation Val279Ile in domain 3 of VEGFR2;
• SNP1719A/T (rs1870377, in exon 11), that corresponds to a
mutation Q472H in domain 5 of VEGFR2.
SNP1192G/A is more interesting for our study because is located
in the domain 3 of VEGFR2, included in aflibercept, and precisely
in a beta sheet (one of the two anti-parallel beta sheets) where
the residue interacts with other hydrophobic residues. Valine and
isoleucine are both hydrophobic, however the isoleucine is more
bulky than valine, and Val279Ile mutation might influence the
stability of the beta sheets of domain 3. This mutation, along
to other SNPs of VEGFRs, is worthy to be studied with the
computational approach hereby described.
A recent binding study (Yang et al., 2014) reported an
affinity of ranibizumab for VEGFA higher than that of
aflibercept. At variance with computational studies, however,
experimental binding data appear significantly influenced by the
methodology used (Wang and Yang, 2013; Yadav et al., 2014).
We have found correspondence between predicted1Ebinding and
contributing energy terms to the kinetic and affinity parameters
of ranibizumab, bevacizumab and aflibercept, measured by
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TABLE 6 | Energy decomposition of predicted 1Ebinding.
anti-VEGF Favorable contributions of residues in anti-VEGF
binding domain
Ranibizumab Thr 105 (−56), Tyr 101 (−115), His 31(−129)
Fab-bevacizumab Ser 105 (−44), His 101 (−82), Asn 31 (−22)
VEGFR1d2_R2d3 Arg 154 (−171), Lys 157 (−190), Lys 165(−157), Lys
166 (−129), Arg 128 (−123), Lys 72 (−112), Lys 43
(−118), Lys 89 (−93), Arg 96 (−167)
Values in brackets correspond to energy contribution of the residues (KJ/mol).
Surface Plasmon Resonance (SPR) by Papadopoulos et al. (2012),
who used captured anti-VEGF agents in the matrix and free
ligands (VEGFA, VEGFB and PlGF) in the eluent. In contrast,
the other SPR setup has used captured VEGFA and free anti-
VEGF agents. In this latter setup, the finding that affinity of
ranibizumab for VEGFA results greater than that of aflibercept
is likely to depend on the blocked access of aflibercept to both
ends of VEGFA (Yang et al., 2014).
Protein contact network approach provides a complementary
analysis of evolution time for different topological properties
of complexes. Fluctuations around a relative conformational
minimum were characterized by properties that varied according
to given constraints, whereas the energetic descriptor of
proteins (dGsolv) did not change over the time, indicating that
MD frames represented relative conformational minimum.
The clustering of protein contact network revealed in the
VEGFR1d2_R2d3/VEGFA that interaction wiring of VEGFA
was conserved in comparison to the other two complexes,
where the VEGFA network was altered. Furthermore, clustering
of protein contact network of ranibizumab/VEGFA and Fab-
bevacizumab/VEGFA was similar but not identical, because
VEGFA showed a greater number of long-range interactions
toward ranibizumab, in comparison to Fab-bevacizumab.
Protein contact networks are built mainly considering VdW
interactions; the observation that clustering of VEGFA in
ranibizumab/VEGFA and Fab-bevacizumab/VEGFA was altered
may be accounted for the higher contribution of VdW in such
complexes, as observed with docking and MM-PBSA.
Some controversy exists about the correct length of MD (Dror
et al., 2010; Genheden and Ryde, 2010, 2012). Long time scale
simulation, in the micro- to millisecond range, is necessary
whenever the phenomena observed are in evolution (e.g.,
binding and unbinding processes, protein folding, conformation
transition) (Dror et al., 2010). In the present study we have
simulated preformed macromolecular complexes in a water
environment in order to carry out MM-PBSA, i.e., analysis
of binding energy. To this end, the nanosecond scale seems
adequate. Within this time scale, it has been shown that MM-
PBSA carried on short (20 ns) independent replicas gives results
comparable to a single longer simulation (Genheden and Ryde,
2010, 2012). Furthermore, longer simulations certainly increase
sampling size ofMD, but would not affectMM-PB(GB)SA results
(Genheden and Ryde, 2012).
Our data may provide a theoretical basis for understanding
differences in affinity for VEGFA of clinically used anti-VEGFs.
Such differences may impact the pharmacodynamics and the
therapeutic effectiveness of these biological drugs. However,
the clinical outcomes of the VEGF Trap-Eye: Investigation of
Efficacy and Safety in Wet AMD (VIEW) studies (Schmidt-
Erfurth et al., 2014) indicate that ranibizumab and aflibercept
are comparable with respect to the number of treatments
and visual acuity gains when dosed in identical regimens and
concentrations (0.5mg). The clinical outcomes of Comparison
of Age-related Macular Degeneration Treatments Trials (CATT)
studies (Martin et al., 2012) indicate that ranibizumab and
bevacizumab are equally effective on visual acuity over a 2-year
period when used in same regimens but at different doses (0.5
and 1.25mg for ranibizumab and bevacizumab, respectively).
The same studies indicate that the proportion of patients
with 1 or more systemic serious adverse events was higher
with bevacizumab than ranibizumab (39.9 vs. 31.7%; adjusted
risk ratio, 1.30; 95% CI, 1.07–1.57; P = 0.009). In general,
affinity alone, even when it is assessed with high accuracy,
does not always straightly correlate with clinical outcome. In
fact, between affinity and clinical outcomes there are potency,
dose, and regimen parameters to take into account in order
to translate in silico, in vitro, and in vivo data from bench to
bedside.
Here we presented in silico data of anti-VEGF/VEGFA
complexes showing that they considerably differ both in
terms of molecular interactions and stabilizing energy. Detailed
understanding of such drug-target interactions may help in
developing novel biological drugs.
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